1. Home
  2. Labeler Index
  3. Aphena Pharma Solutions - Tennessee, Llc
  4. 43353-863
  5. Product Images: Gabapentin

Product Images Gabapentin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Gabapentin NDC 43353-863 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 100mg - 43353 862 60

Bottle Label 100mg - 43353 862 60

This is a product description of Gabapentin, which comes in 90 capsules with a strength of 100mg each. The NOC number is also provided for identification purposes.*

Bottle Label 300mg - 43353 863 30

Bottle Label 300mg - 43353 863 30

This is a drug called Gabapentin and the given text appears to be a National Drug Code number for it. It is not enough information to provide a detailed description of the drug itself.*

Bottle Label 400mg - 43353 864 60

Bottle Label 400mg - 43353 864 60

Gabapentin is a medication that comes in the form of 400mg capsules. The total quantity is 90 capsules. It is not clear what the source or purpose of this medication is from the provided text.*

Aphena Pharma Solutions - TN - Aphena

Aphena Pharma Solutions - TN - Aphena

Figure 1. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1 - gabapentin fig1

Figure 1. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1 - gabapentin fig1

The text shows a chart with the mean pain score over the course of a clinical trial that consisted of a 4-week dose titration period followed by a 4-week fixed dose period. The chart includes two groups: a placebo group and a group taking 3600 mg/day of gabapentin. The data shows that at the end of the study, the group taking gabapentin had a significantly lower mean pain score than the placebo group (p<001).*

Figure 2. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2 - gabapentin fig2

Figure 2. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2 - gabapentin fig2

This appears to be a graph showing the mean pain score over time during a dose titration period of three weeks and a fixed dose period of four weeks. The X-axis represents the weeks and the Y-axis represents the pain score. The pain score is measured for placebo, as well as for two different doses of Gabapentin (1800 mg/day and 2400 mg/day). The graph shows a decrease in pain score over time for both Gabapentin doses compared to placebo. The significance level (p-value) is also shown as being less than 0.05 for both doses.*

Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies - gabapentin fig3

Figure 3. Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies - gabapentin fig3

Percentage of Responders at Endpoint for Study 1 and Study 2 are provided in the text. No further information is available.*

Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with Partial Seizures - gabapentin fig4

Figure 4. Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients ≥12 Years of Age with Partial Seizures - gabapentin fig4

Chemical Structure - gabapentin str

Chemical Structure - gabapentin str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.